Navigation Links
Study of Cell Therapeutics' Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
Date:6/17/2012

SEATTLE, June 18, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced that the University of Washington ("UW") has begun enrolling patients in a randomized phase II study testing the combination of tosedostat with either cytarabine or decitabine for elderly patients with newly-diagnosed acute myeloid leukemia ("AML") or high-risk myelodysplastic syndrome ("MDS"). 

Drs. John Pagel and Elihu Estey, from the University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, are leading the study.

"This is the first study to examine the effects of tosedostat in combination with either cytarabine or decitabine as a first-line therapy.  The study will evaluate how well patients tolerate these combinations, and their effectiveness.  Given that there have been no major advances in treatment of elderly patients with AML, and the results of a previous study of tosedostat by itself in relapsed or refractory patients with AML or MDS showed promising anti-leukemic effects and acceptable tolerability, we are hopeful that this study will demonstrate that tosedostat increases the limited efficacy of these commonly used anti-leukemic agents," Dr. Estey said.

The study's primary objectives are to determine the four-month survival and complete response ("CR") rates of tosedostat in combination with either cytarabine or decitabine in untreated AML or high-risk MDS. The study's secondary objectives are to assess the safety and tolerability of tosedostat in combination with either cytarabine or decitabine, to determine the treatment-related mortality rate (defined as death within the first 30 days of beginning treatment), and to estimate the rates of disease-free survival, one-year survival, and overall survival.   

About the Study

Each arm of the study will enroll up to 20 patients, with the possibility of enrolling an additional five patients each (for a ma
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Positive Clinical Study Results for BSPs HyperQ Technology
2. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
3. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
4. Marshall study shows nanoparticles used as additives in diesel fuels can travel from lungs to liver
5. Clionsky Neuro Systems (CNS-Neuro) Announces Publication of Study Finding Elderly Patients Unable to Recognize Their Memory Loss
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
8. Singapore scientists lead human embryonic stem cell study
9. GeneTex Antibody Company to Launch New Line of Primary Antibodies for the Study of Spindle Assembly
10. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
11. Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... PAREXEL International Corporation (Nasdaq: ... organization , announced today that the Company ... all of the business assets of privately-owned Quantum ... specialized pharmacovigilance services, based in Chandigarh, India.  ... monitoring, and prevention of adverse effects with ...
(Date:3/26/2015)... "In America," the popular news television program ... is hosted by legendary film actor James Earl Jones, has ... an upcoming segment. , Botany is commonly described as ... actually quite a bit more complicated than that. Scientists and ... living organisms, from the smallest bacteria known to man to ...
(Date:3/26/2015)... NJ (PRWEB) March 26, 2015 WriteResult, ... partnered with researchers from Yale University’s School of Public ... by study participants during a 4 month-long project. The ... of providing low income families with free access to ... habits and diet-related health concerns like high blood pressure, ...
(Date:3/25/2015)... Agnition announced today that it will ... airing for the first time at 7:30 a.m. CST ... will explore the extremely important role soil microbes perform ... patented Microbial Catalyst™ technology that enhances soil and plant ... will air again on April 28. , A biochemist ...
Breaking Biology Technology:PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2
... Shareholders Re-elect Directors and Ratify Auditor at Annual Meeting, ... Directors,of Baxter International Inc. (NYSE: BAX ) today ... Annual Meeting of Shareholders,held earlier today., Baxter,s Board ... of Baxter common stock. This payment represents a continuation ...
... 6 There are a lot of steps,between a ... force must be involved with many of those steps ... re-launch effort,according to a study by benchmarking leader Best ... force? Half of the companies that,participated in the research ...
... - Dalton Pharma Services, a privately ... Fisher Scientific,have entered into an agreement ... proprietary,Thermo Fisher manufacturing process to produce ... enzyme-based technology developed at Thermo Fisher,Scientific,s ...
Cached Biology Technology:Invigorated Sales Force Key to a Successful Re-Launch 2Dalton Pharma Services Licenses Thermo Fisher Scientific Technology to Produce Polynucleotides for Drug Development 2Dalton Pharma Services Licenses Thermo Fisher Scientific Technology to Produce Polynucleotides for Drug Development 3
(Date:3/10/2015)...  Continuing its 167-year history of offering the Best, ... The Eye Scanning Password Authenticator , a device that ... websites or sensitive data. Employing the same ... the device has a small camera that scans and ... converting them into an encrypted ID that cannot be ...
(Date:3/5/2015)... , March 5, 2015 In ... percent of companies already using these solutions and 42 percent ... Of the latter, approximately 25 percent of the companies will ... While the majority of companies in the region are ... that the hybrid model will command significant attention in the ...
(Date:3/2/2015)... Ala. , March 2, 2015  Businesses ... processing. Data protection company Tharon Rankins Enterprises has ... that provides an ultra-safe way for businesses to ... their financial transactions. Beconux is ... Tharon Rankins Enterprises. Functioning similarly to an ATM ...
Breaking Biology News(10 mins):Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Personal Data Protection Company Launches New Product 2
... clinical trial, a new drug that selectively blocks ... acute kidney transplant rejection as cyclosporine, the standard ... experimental drug, a co-stimulatory blocker called belatacept (LEA29Y), ... of the toxic side effects associated with standard ...
... and chimpanzees both pass on "traditions" to other members ... feeding behaviour. The findings add to evidence that cultural ... involved killerwhales at Marineland in Niagara Falls in Ontario, ... to catch birds, and passed the strategy on to ...
... mast cells, known to play a central role in ... that can kill these cells by programming them to ... move researchers another step closer to understanding the life ... new treatments for allergy and inflammatory responses in arthritis, ...
Cached Biology News:New type of rejection blocker protects kidneys after transplant 2New type of rejection blocker protects kidneys after transplant 3New type of rejection blocker protects kidneys after transplant 4More animals join the learning circle 2Climate model links higher temperatures to prehistoric extinction 2
... The CHEMICON Re-Blot Plus Western Blot ... removal of antibodies from Western blots that ... iodine or other isotopes. It is not ... 4-chloronapthol, etc.), as it is not possible ...
... as a 5x solution. Designed to ... proteins without destroying antigenic binding capacity. ... signals from blots. Not recommended for ... a 5X solution sufficient to strip ...
... designed for two-dimensional electrophoresis (2D) and ... in this marker have been selected ... a 2D gel. The pI range ... Mol wt: 17,000-89,000 Physical Form: ...
High-throughput DNA preparation and end sequencing of BAC libraries. 3730xl DNA sequencers. LIMS tracking utilizing Geospiza's Finch system. Full-length BAC sequencing also available. Our expertise h...
Biology Products: